Biopharmaceuticals: AstraZeneca on Localization of Drug Production
At the site of JSC "NC "KAZAKH INVEST," Chairman of the Board of the National Company Yerzhan Yelekeyev met with Maria Shipuleva, Director of the AstraZeneca representative office in Kazakhstan. The parties discussed the work of a biopharmaceutical company on implementing a project for the contract production of three original medicines in Kazakhstan. The project will be implemented with the support of JSC "NC "KAZAKH INVEST."
The first drug of localization will be Dapagliflozin, the production of which will open up new prospects in the fight against chronic heart failure and chronic kidney disease, providing an innovative alternative to traditional treatment methods.
Olaparib and acalabrutinib will be the next drugs under contract production. Both drugs represent important medical advances in oncology and immunology.
"Localizing drug production will give impetus to the development of the pharmaceutical industry in Kazakhstan, improve the range of medicines, increase the effectiveness of therapy, and improve the quality of medical care," Yerzhan Yelekeyev said.
In turn, Dinara Isabekova, Industry Executive with the Task Force Department of JSC "NC "KAZAKH INVEST," noted that implementing the AstraZeneca project in Kazakhstan will allow Kazakhstani patients unhindered access to innovative medicines.
Following the meeting, agreements were reached to continue close cooperation and strengthen mutually beneficial cooperation in the pharmaceutical industry of Kazakhstan.
